Pfizer will not cut sales force
"The last thing we are going to do is pull back on our field force and our number of sales reps given the nature of our new product potential," Pfizer CFO David Shedlarz told the Merrill Lynch pharmaceutical and biotech conference Feb. 5 in New York City. Shedlarz noted that there has been speculation about the possibility of companies cutting back on sales reps in light of the increasing focus on compliance and relative lack of new product launches. [Editor's Note: More coverage of Shedlarz' discussion of the dynamics in marketing and sales will appear in 1"The Pink Sheet" DAILY Feb. 9. Visit our website, www.ThePinkSheetDAILY.com, to sign up for a free trial.]...
You may also be interested in...
Early results from its novel antiviral are encouraging, but demonstrating life-saving qualities in a short window of time will be tricky.
After federal agencies invested almost $5600m to ensure Cue Health could scale up production, FDA announces the self-administered test will be available OTC. it's the agency's first emergency use authorization for an at-home molecular diagnostic test available nonprescription.
Tezepelumab was among four products that the European Medicines Agency most recently considered for review under its accelerated assessment mechanism.